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Abstract
 
We previously described a mechanism for the maintenance of peripheral self-tolerance. This
involves the cross-presentation of tissue-associated antigens by a bone marrow–derived cell
type that stimulates the proliferation and ultimate deletion of self-reactive CD8 T cells. This
process has been referred to as cross-tolerance. Here, we characterize the elusive cell type re-
 
sponsible for inducing cross-tolerance as a CD8
 
 
 
 
 
 dendritic cell (DC). To achieve this aim,
transgenic mice were generated expressing yellow fluorescent protein (YFP) linked to CTL
epitopes for ovalbumin and glycoprotein B (gB) of herpes simplex virus under the rat insulin
promoter (RIP). Although tracking of YFP was inconclusive, the use of a highly sensitive gB-
specific hybridoma that produced 
 
 
 
-galactosidase on encounter with antigen, enabled detec-
tion of antigen presentation by cells isolated from the pancreatic lymph node. This showed
that a CD11c
 
 
 
CD8
 
 
 
 
 
 cell was responsible for cross-tolerance, the same DC subset as previ-
ously implicated in cross-priming. These data indicate that CD8
 
 
 
 
 
 DCs play a critical role in
both tolerance and immunity to cell-associated antigens, providing a potential mechanism by
which cytotoxic T lymphocyte can be immunized to viral antigens while maintaining toler-
ance to self.
Key words: antigen presentation • cross-tolerance • CD8
 
 
 
 T cells • dendritic cells • cross-
presentation
 
Introduction
 
When CTLs develop in the thymus, autoreactive cells are
deleted from the repertoire (1). However, some self-anti-
gens are not expressed in the thymus, requiring additional
tolerogenic mechanisms to operate outside the thymus (2).
One way naive CTLs can be tolerized in the periphery is
by the delivery of an antigenic signal in the absence of co-
stimulation (3, 4), as would occur when most tissue cells of
the body present their antigens. However, T cells recircu-
late primarily within the secondary lymphoid compartment
(e.g., the spleen, blood, and LNs) and, while naive, would
not directly encounter self-antigens on most peripheral
tissues. If direct encounter were the only way to induce
tolerance, an array of autoreactive T cells would not be tol-
erized and would be available for activation by licensed
dendritic cells (DCs) carrying self-antigens together with
pathogen antigens from peripheral sites of infection.
To overcome this potential driving force for autoimmu-
nity, the immune system has evolved a mechanism by
which it can induce tolerance to cellular antigens derived
from tissues outside the secondary lymphoid compartment.
This process has been termed cross-tolerance (5, 6). This
involves a subset of specialized bone marrow–derived anti-
gen-presenting cells that are able to capture antigens from
tissue cells and present them on MHC class I molecules for
recognition by naive CTL (7). Upon recognition of these
self-antigens, autoreactive CTL undergo proliferation but
are ultimately deleted from the peripheral T cell repertoire.
While it has been clear for some years that the cell type re-
sponsible for inducing cross-tolerance is bone marrow–
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derived (7, 8), direct identification of this important cell
type has yet to be achieved.
Recently, there has been some suggestion that DCs,
which are normally considered the premium cell type for
initiating strong immunity to foreign antigens, might also
play a role in the induction of tolerance (9–12). Hawiger et
al. (11) provided evidence that targeting of antigen to
DEC-205, expressed primarily by DCs, led to tolerance in-
duction. Kurts and colleagues (9) used transgenic expres-
sion of antigen-presenting molecules to implicate CD11c
 
 
 
DC in cross-tolerance. More recently, Hugues et al. (12)
reported that islet apoptosis induced by streptozotocin
could initiate presentation of antigen by a CD11b
 
 
 
 DC
subset that stimulates immunoregulatory cells in NOD
mice. While these studies implicate DCs in self-tolerance,
precise identification of the DC subset responsible for con-
stitutive induction of cross-tolerance to peripheral self-anti-
gens has not been achieved. Here, we examine the pheno-
type of this elusive cell type.
 
Materials and Methods
 
Mice.
 
All mice were between 6 and 12 wk of age. Generation
of OT-I and gBT-I.1 (gBT-I) mice has been described previously
(13, 14).
 
Generation of Rat Insulin Promoter YSS Mice.
 
Rat insulin pro-
moter (RIP)-YSS mice were generated by cloning the RIP into
the enhanced yellow fluorescent protein vector (pEYFP; CLON-
TECH). A polytope encoding the CD8
 
 
 
 T cell determinants
OVA
 
257–264
 
 (SIINFEKL) and gB
 
498–505
 
 (SSIEFARL) from OVA
and Herpes simplex virus-1, respectively, was produced by an-
nealing of complementary oligonucleotides (5
 
 
 
-CATGGAGAG-
TATAATCAACTTTGAAAAACTGACTACCTCCTCCATC-
GAGTTCGCCCGGCTGCAGGG-3
 
 
 
 and 5
 
 
 
-CATGCCCT-
GCAGCCGGGCGAACTCGATGGAGGAGGTAGTCAGTT-
TTTCAAAGTTGATTATACTCTC-3
 
 
 
). This was inserted at a
NcoI/StyI site between the RIP and EYFP constructs. Vector se-
quences were excised by digestion at BamHI sites. DNA was mi-
croinjected into pronuclei of B6 fertilized eggs as described previ-
ously (15). DNA was prepared from tails of RIP-YSS mice and
analyzed by PCR. The DNA encoding RIP-YSS was amplified
by PCR using oligonucleotide primers 5
 
 
 
TACCTACCCCTC-
CTAGAGCCCTTA and 3
 
 
 
TGATATAGACGTTGTGGCTG-
TTGTAGT which cover a 550-bp fragment, or 5
 
 
 
GCTACC-
CCGACCACATGAA and 3
 
 
 
TGCTTGTCGGCCATGATA-
TAG which cover a 252-bp product. Amplified DNA was de-
tected on a 2% agarose gel containing ethidium bromide.
 
Analysis of T Cell Deletion.
 
Recipients were injected with 4 
 
 
 
10
 
6
 
 gBT-I cells. After 7 wk, cells were pooled from the LNs
(inguinal, brachial, axillary, sacral, cervical, and mesenteric) and
spleen of individual mice. They were then stained using anti-
V
 
 
 
8.1/8.2-FITC (MR 5–2), anti–V
 
 
 
2-PE (B20.1), and anti–
CD8
 
 
 
-APC (53–6.7; BD PharMingen). Live gates were set on
lymphocytes by forward and side scatter profiles. Analysis was
done on a FACScan™ (Becton Dickinson). 10,000–20,000 live
cells were collected for analysis. gBT-I cells were identified as
V
 
 
 
2
 
 
 
 V
 
 
 
8
 
 
 
 CD8
 
 
 
 cells (14). The proportion of endogenous
V
 
 
 
2
 
 
 
 V
 
 
 
8
 
 
 
 CD8
 
 
 
 cells (
 
 
 
2%) was assessed by examining mice
that did not received gBT-I cells as described previously (7).
This value was subtracted from the values derived from gBT-I re-
cipients.
 
DC Isolation.
 
DCs were isolated essentially as described pre-
viously (16, 17). Antibodies used in the depletion cocktail were
anti-CD3 (KT3), anti-Thy1 (T24/31.7), anti-CD19 (ID3), anti–
GR-1 (RB6–8C5), and anti-erythrocyte (TER-119).
 
Detection of Antigen Presentation by LN DCs.
 
The 
 
lacZ
 
-induc-
ible gB HSV-specific hybridoma (HSV-2.3.2E2; references 18
and 19) was maintained in DMEM containing 10% FCS, 50 
 
 
 
M
2ME, 2 mM 
 
L
 
-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin (hybridoma media). Stimulator cells were released
from the LNs by collagenase/DNase digestion for 20 min fol-
lowed by a 5-min incubation with 0.099 M EDTA. Some prepa-
rations were depleted of CD11c, CD11b, or CD8
 
 
 
 populations
by incubating LN cells in predetermined optimal concentrations
of N418, M1/70, or 53–6.7, respectively, for 30 min. Cells were
then washed through an underlay of FCS containing EDTA, and
then in balanced salt solution containing EDTA (BSS-EDTA).
Finally, antibody-bound cells were removed using sheep anti–rat
IgG Dynabeads and the remaining cells washed once in BSS-
EDTA, once in hybridoma medium, and then resuspended in
hybridoma medium. The efficiency of depletion was examined
by staining depleted and undepleted preparations with goat anti–
rat IgG-FITC (Caltag) for 30 min with analysis by flow cytome-
try. Residual specific cell populations were reduced to 
 
 
 
0.15% of
the total live LN cells (unpublished data). Depleted or undepleted
lymph node cells, or purified DC subsets, were cultured with 10
 
5
 
HSV-2.3.2E2 cells for 24 h in 200 
 
 
 
l hybridoma media in 96-
well, flat-bottomed plates (Falcon, Becton Dickinson). Then,
cells were washed in PBS and fixed using 100 
 
 
 
l PBS containing
1% formaldehyde and 0.2% glutaraldehyde for 5 min at 4
 
 
 
C. The
plates were washed with PBS and then overlaid with 50 
 
 
 
l of a
solution containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-
 
 
 
-
 
D
 
-
galactoside, 5 mM potassium ferrocyanide, 5 mM potassium ferri-
cyanide, and 2 mM MgCl
 
2
 
 in PBS. Cultures were examined mi-
croscopically and the number of blue cells counted after 8–12 h
incubation at 37
 
 
 
C.
 
Results and Discussion
 
Previously, we reported that expression of OVA in the
pancreatic islets led to cross-presentation of OVA on a
bone marrow–derived cell in the draining LNs (8), and that
this cell induced the deletion of autoreactive OVA-specific
CTLs (7). Despite numerous and varied attempts, we have
never previously been able to isolate the bone marrow–
derived cell from the draining LNs. To improve our ability
to identify the cross-tolerance antigen-presenting cell, we
generated transgenic mice expressing a hybrid fusion pro-
tein under the control of the rat insulin promoter (RIP).
This hybrid protein consists of yellow fluorescent protein
(YFP) linked to two class I epitopes: one from OVA
(OVA
 
257–264
 
) and one from Herpes simplex virus-1 glyco-
protein B (gB
 
498–505
 
). We have termed the hybrid protein
YSS and the transgenic line RIP-YSS.
To determine whether YSS was presented in the drain-
ing LNs, RIP-YSS mice were injected with CFSE-labeled
(7) CD8 T cells from transgenic mice specific for OVA
(OT-I cells) (13) or gB (gBT-I cells) (14), and 3 d later
their LN cells were examined by flow cytometry (Fig. 1).
Both OT-I and gBT-I CD8
 
 
 
 T cells proliferated in the
pancreatic but not inguinal LNs of RIP-YSS mice, indicat- 
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ing that these MHC class I epitopes were expressed in the
pancreas and effectively presented in the draining LNs.
To determine whether presentation of YSS was via
cross-presentation on a bone marrow–derived antigen-pre-
senting cell, we made use of the fact that gB is not pre-
sented by the K
 
bm1
 
 molecules of bm1 mice (unpublished
data). bm1 mice are congenic to B6 mice, differing only at
the H-2K locus. RIP-YSS mice of a B6 background were
lethally irradiated and reconstituted with either RIP-YSS
(B6; H-2
 
b
 
) bone marrow or bm1 (H-2
 
bm1
 
) bone marrow
(8). As a control to exclude possible expression of YSS by
bone marrow–derived cells, we also injected RIP-YSS
bone marrow into irradiated B6 mice. After 10 wk, to al-
low reconstitution of antigen-presenting cells, chimeric
mice were injected with CFSE-labeled (7) gBT-I cells. 3 d
later, the pancreatic and inguinal LNs were recovered and
single cells analyzed by flow cytometry (Fig. 2). Only RIP-
YSS mice receiving RIP-YSS (B6, H-2
 
b
 
) bone marrow
showed proliferation of gBT-I cells, indicating that a bone
marrow–derived cell was responsible for cross-presentation
of islet-derived YSS in the draining LNs.
To ensure that such cross-presentation led to deletion of
naive gB-specific CTLs, RIP-YSS mice or nontransgenic
control mice were injected with 4 
 
 
 
 10
 
6
 
 gBT-I cells and
then 7 wk later examined for the presence of these cells in
the spleen and LNs (Fig. 3). This showed that few gBT-I
cells remained in RIP-YSS mice relative to nontransgenic
controls, indicating that cross-presentation of YSS had
caused the deletion of gB-specific T cells. This finding
confirmed earlier studies where we have shown that
OVA-specific CD8 T cells are deleted in response to
cross-presented OVA in mice expressing membrane-
bound or soluble OVA in the pancreas under the control
of the RIP (7, 20).
Once we had established that cross-presentation of the
YSS self-antigen led to peripheral deletion of autoreactive
CTLs, we asked whether the cell presenting YSS in the
draining LNs could be identified by fluorescence as a con-
sequence of captured fluorescent YSS protein. Using 16–
20 mice per group, we were able to isolate sufficient DCs
from the pancreatic LNs of transgenic mice to examine
fluorescence. This approach was inconclusive, however,
with very poor detection of fluorescence in DCs of the
draining LNs (unpublished data). Failure to detect fluores-
cence was either because the fluorescent YSS molecule was
rapidly degraded after capture or because the APC respon-
sible for presentation was not present in such preparations.
To distinguish between these possibilities, we examined
antigen presentation by LN DCs using a very sensitive T
cell hybridoma that produces 
 
 
 
-galactosidase in response to
stimulation with the MHC class I–restricted gB epitope
(19). Previously, we had been unable to detect in vitro pre-
sentation by pancreatic LN cells from any of our transgenic
lines (RIP-mOVA or RIP-OVA
 
hi
 
) using other methods
such as presentation to TCR transgenic cells (unpublished
Figure 1. gB and OVA-specific T cells proliferate to YSS in the pan-
creatic LNs of RIP-YSS mice. 2   106 CFSE-labeled recombination ac-
tivation gene (Rag)-1 /  OT-I (A and D) or Rag-1 /  gBT-I (B, C, E,
F) CD8  T cells were adoptively transferred into RIP-YSS (A, B, D, E)
or B6 (C and F) recipients. 3 d later, pancreatic (A–C), and inguinal
(D–F) LNs were analyzed by flow cytometry, gating on CD8 CFSE PI 
cells (reference 7).
Figure 2. A bone marrow–derived cell type cross-presents YSS in RIP-
YSS mice. Bone marrow chimeric mice were generated using RIP-YSS
(A, C, D, F) or nontransgenic littermate (B and E) recipients. Lethally
irradiated (2   550 cGray, 3 h apart) recipients were engrafted with T
cell–depleted RIP-YSS (H-2Kb, B6 background)(A, B, D, E) or H-2Kbm1
mutant bone marrow (C and F). After 10 wk reconstitution, 2   106
CFSE-labeled recombination activation gene (Rag)-1 /  gBT-I CD8  T
cells were adoptively transferred into bone marrow chimeric recipients.
3 d later, the pancreatic (A–C) and inguinal (D–F) LNs were analyzed by
flow cytometry. Histograms are gated on CD8 CFSE PI  cells.
Figure 3. Cross-presentation of endogenous antigen induces deletion
of antigen-specific CD8  T cells. 4   106 gBT-I CD8  T cells were
adoptively transferred into RIP-YSS transgenic mice or nontransgenic
littermates. After 7 wk, the number of gBT-I cells in the LNs and spleen
was determined by flow cytometry (reference 7). Individuals (white cir-
cles) and means (—) for each group are shown. 
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data). In our first experiments using the 
 
 
 
-galactosidase
producing hybridoma, we removed pancreatic LNs from
RIP-YSS mice or nontransgenic controls and then gener-
ated single cell suspensions by digestion with collagenase
and DNase; an approach developed to minimize damage to
DCs (16). After digestion, the entire cell mix derived from
the pancreatic LNs was cultured for 24 h with cells from
the gB-specific hybridoma. After this time, cultures were
developed for 
 
 
 
-galactosidase expression, and positive cells
enumerated (Fig. 4 A). This revealed that cells capable of
presenting YSS-derived gB to CD8 T cells were present in
the LN cell preparation. To further characterize the cell
presenting islet antigens in the pancreatic LNs, mixed cell
populations were depleted of cells expressing the markers
CD11c, CD8, or CD11b, and then tested for presentation
of YSS (Fig. 4 B). As shown, the antigen-presenting cells
were CD11c
 
 
 
, indicating that they belonged to the DC
lineage. Furthermore, this cell type was depleted by anti-
CD8
 
 
 
, but not anti-CD11b mAb, indicating it was a
CD8
 
 
 
 
 
CD11b
 
  
 
DCs. It has recently been described that
some CD11b
 
 
 
CD8   DCs can convert to CD8   after
antigen encounter (21). This same subset is unlikely to rep-
resent the cross-tolerance CD8   DCs which is CD11b 
(Fig. 4 B) and can be found expressing CD8  within the
pancreatic islets (unpublished data).
To confirm that CD8   DCs were responsible for cross-
tolerance, we sorted CD11c CD8   and CD11c CD8  
DCs from the pancreatic LNs of RIP-YSS mice and exam-
ined their ability to stimulate the gB-specific hybridoma
(Fig. 5). This required 29 mice to recover 11,500 CD8  
DCs, so we were only able to do a titration of DCs from
5,750 cells per well with a single well per dilution. In this
case, however, CD8   DCs clearly stimulated gB-specific
hybridoma cells in a dose-dependent manner, with no re-
sponse generated by CD8   DCs.
CD8   DCs were recently shown to be responsible for
cross-priming (22) when mice were immunized with for-
eign antigen in the form of OVA-loaded splenocytes (23).
As in our example here, which involves cell-associated YSS
antigen, the cross-priming observed by den Haan et al. (23)
involved a cell-associated antigen, which appears to be pre-
ferred for cross-presentation (24).
There is now strong evidence that dying cells are very
efficiently targeted for cross-presentation by the CD8  
DC subset (25). Whether the cross-presentation associated
with cross-tolerance also requires apoptotic cells or can
present antigens from living cells is unclear. However, it is
apparent that cross-presentation can be enhanced by caus-
ing tissue destruction (26), but whether this leads to the
same sort of deletional response of autoreactive CD8 T
cells as seen with constitutive cross-tolerance has not been
examined. Recently, destruction of NOD islets by strepto-
zotocin was shown to enhance islet antigen presentation to
CD4 T cells by a CD11b  DC subset (12). This led to in-
duction of immunoregulatory cells that prevented autoim-
munity. The CD11b  identity of the DC subset mediating
presentation in the report by Hugues et al. (12) is surpris-
ing, as a recent publication by Inaba and colleagues pro-
vides strong evidence that CD11b CD8   DCs are re-
sponsible for the capture and presentation of apoptotic cells
in vivo (25). Perhaps this relates to a differences between
NOD and B6 mice, or to differences in APCs targeted by
injecting foreign apoptotic cells versus those generated by
streptozotocin treatment. It is unclear why our data and
Hugues et al. (12) implicate different DC subsets, but per-
haps this relates to differences in class I versus class II re-
stricted responses or constitutive versus damage-induced
cross-presentation.
Given that CD8   DC subset appears to be responsible
for induction of both cross-tolerance and cross-priming,
what are the mechanisms that select between these oppos-
ing outcomes? One possibility is that CD8   DCs may be
further subdivided into immunogenic and tolerogenic sub-
sets. More likely, however, is that tolerance induction is
the default outcome, and that additional stimuli associated
with foreign antigens are responsible for their immunoge-
Figure 4. Identification of the
cell type responsible for cross-
presentation of islet antigens. LN
cells were isolated from RIP-YSS
mice or nontransgenic B6 con-
trols and subjected to collagenase
and DNase digestion to release
DCs. The preparations were ei-
ther left (A) undepleted or (B)
depleted of various populations
including rat Ig  (negative con-
trol), CD11c , CD11b , or
CD8   cells using magnetic
beads. These populations were
then tested for their ability to
stimulate lacZ production by the
T cell hybridoma HSV-2.3.2E2,
specific for gB (reference 19). The equivalent of one pancreatic LN
(5–8   105 cells) or 1/4–1/10 of an inguinal LN (4–8   106 cells) was
placed into each well containing 105 hybridoma cells and cultured for 24 h
at 37 C. Error bars indicate SD of triplicate wells. The experiments
shown in A and B were performed 6 and 3 times, respectively. Data
were collected blind.
Figure 5. Isolation of the cell
type responsible for cross-pre-
sentation of islet antigens. Pan-
creatic LNs were removed from
RIP-YSS mice and digested
with collagenase and DNase.
The preparations were then en-
riched for DCs by magnetic bead
depletion of other cells (Materi-
als and Methods). Finally, DC-
enriched populations were
stained with anti-CD11c, anti-
CD45RA, and anti-CD8  and
sorted for CD11c CD45RA 
cells that were either CD8   or
CD8  . CD45RA was used to
exclude plasmacytoid DCs. The CD8   and CD8   DCs were titrated
and used to stimulate the gB-specific hybridoma. CD8   DCs were re-
covered in small numbers that only allowed analysis of single wells per di-
lution, whereas CD8   DCs were titrated in duplicate and the mean
count shown. This experiment was performed twice with similar results.1103 Belz et al. Brief Definitive Report
nicity (4, 27). Other studies support the notion that the
CD8   DC subset can be converted to an immunogenic
form by CD40 signaling (28, 29), indicating that the im-
munogenicity of these DCs can be influenced by environ-
mental signals. This dual role for a DC subset is likely to be
very important in limiting autoimmunity, since under non-
infectious conditions the CD8   DCs can induce periph-
eral tolerance to self-antigens, deleting autoreactive T cells
and leaving only pathogen-specific T cells to respond to li-
censed DCs during infections, when a mixture of pathogen
and cellular products will be presented.
In summary, our data indicate that the CD8   DC sub-
set is responsible for induction of peripheral self-tolerance
by their ability to capture and cross-present tissue-associated
antigens to naive CTLs. These DCs appear to represent an
important subset for several reasons, including their ability
to capture cell–associated antigens (25), their ability to
present such antigens to both CD4 and CD8 T cells (30),
and their ability to induce either tolerance (shown here) or
immunity (23) depending on the nature of the antigen.
This knowledge greatly advances our capacity to study the
signals that decide between immunity and tolerance.
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